Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 4.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,587,541 shares of the specialty pharmaceutical company's stock after purchasing an additional 72,007 shares during the period. JPMorgan Chase & Co. owned about 2.63% of Jazz Pharmaceuticals worth $195,506,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. IFP Advisors Inc purchased a new position in Jazz Pharmaceuticals during the 4th quarter worth $25,000. CoreFirst Bank & Trust bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $28,000. Jones Financial Companies Lllp increased its stake in shares of Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after buying an additional 130 shares during the period. UMB Bank n.a. raised its holdings in shares of Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after acquiring an additional 129 shares in the last quarter. Finally, Lindbrook Capital LLC lifted its stake in Jazz Pharmaceuticals by 82.6% in the fourth quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company's stock worth $48,000 after acquiring an additional 176 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded down $10.78 during trading on Friday, reaching $110.04. The company had a trading volume of 2,171,302 shares, compared to its average volume of 755,523. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a market cap of $6.68 billion, a price-to-earnings ratio of 15.50, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The firm has a 50-day simple moving average of $132.27 and a 200-day simple moving average of $122.99.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the transaction, the chief executive officer now directly owns 439,744 shares in the company, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of the company's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. This represents a 7.95 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,736 shares of company stock worth $4,023,305. Company insiders own 4.20% of the company's stock.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of research reports. JPMorgan Chase & Co. raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Barclays reissued an "overweight" rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Piper Sandler reaffirmed an "overweight" rating and set a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their price target for the company from $145.00 to $179.00 in a report on Friday, March 7th. Finally, Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.